Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $9.23M fell 20.5% year over year, ahead of the -61.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.4% from the prior quarter.
Context
- Selling, general & admin amounted to 74.9% of revenue in FY2025, down 349.4 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $37.35M (+0.1%) for the fiscal year ending Dec 2026, a step up from the -71.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.23M+5.4% QoQ
- Last fiscal yearDec 2025
- $37.32M-71.7% YoY
- LTMMar 2026
- $34.94M-61.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.5% | -57.4% | -36.9 pp |
| 1 year | -71.7% | +0.1% | +71.8 pp |
| 3-year CAGR | — | +26.6% | — |
| 5-year CAGR | +47.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 37.32M USD
- Year-over-year change
- -71.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.32M | -71.7% |
| FY2024 | 2024-12-31 | 131.9M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Selling, General & Admin vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 selling, general & admin of $34.94M is the 7th highest of the 11 companies compared; the peer median is $87.2M.
- Its year-over-year change of -61.3% is the lowest of 11, against a peer median of +10.5%.
- Selling, general & admin amounts to 50.2% of revenue for LXRX, versus a peer median of 43.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Jun 2026 | $351.33M | +8.3% | +2.1% | 34.8% | |
| LTM Jun 2026 | $337.33M | +6.9% | +29.8% | 35.9% | |
| LTM Mar 2026 | $173.21M | +78.5% | +16.4% | 48.0% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $34.94M | -61.3% | — | 50.2% | |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $24.75M | -6.4% | -9.4% | 347.5% | |
| LTM Sep 2026 | $19.78M | +34.5% | +16.3% | — | |
| LTM Mar 2026 | $9.79M | +21.7% | +16.7% | — | |
| Peer median (excluding LXRX) | $87.2M | +10.5% | +16.3% | 43.8% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Cost of Revenue | 55.05M | 52.52M | 58.97M | 616K | 274K |
| Gross Profit | (54.75M) | (52.38M) | (57.77M) | 30.47M | 49.53M |
| Gross Margin | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| Research & Development | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Selling, General & Admin | 0 | 0 | 0 | 131.9M | 37.32M |
| Operating Expenses | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| EBITDA | (86.66M) | (100.03M) | (169.76M) | (184.29M) | (41.38M) |
| EBITDA Margin | -29081.9% | -71966.2% | -14099.3% | -592.9% | -83.1% |
| Operating Income | (87.09M) | (100.76M) | (171.75M) | (197.12M) | (48.91M) |
| Operating Margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Interest Income | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income / Expenses | (668K) | (1.18M) | (5.37M) | (3.29M) | (1.43M) |
| Income Before Tax | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Pre-Tax Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Net Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (Basic) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| EPS (Diluted) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| Weighted Avg Shares | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Weighted Avg Shares (Diluted) | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.